1	COVID-19 convalescent plasma for the treatment of immunocompromised patients: a
2	systematic review.
3	
4	Jonathon W. Senefeld ¹
5	Massimo Franchini ²
6	Carlo Mengoli ²
7	Mario Cruciani ²
8	Matteo Zani ²
9	Daniele Focosi ^{3,#}
10	Arturo Casadevall ⁴
11	Michael J Joyner ¹
12	
13	¹ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA;
14	joyner.michael@mayo.edu.
15	² Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;
16	massimo.franchini@asst-mantova.it
17	³ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
18	⁴ Department of Medicine, Johns Hopkins School of Public Health and School of Medicine,
19	Baltimore, MD, USA; acasade1@jhu.edu.

- 20 [#]corresponding author: <u>daniele.focosi@gmail.com</u> .
- 21

- 22 Abbreviations: CCP: COVID-19 convalescent plasma; nAb: neutralizing antibodies; VOC: variant
- 23 of concern.
- 24 Keywords: convalescent plasma; COVID-19; SARS-CoV-2; immunosuppression.
- 25 Author contributions: J.W.S. and M.Z. performed literature searches; C.M. and M.C. performed
- statistical analyses; M.F. and D.F. wrote the first draft; A.C. and M.J.J. revised the final version.

27 Abstract

Immunosuppressed patients have increased risk for morbidity and mortality from COVID-19 28 29 because they less frequently mount antibody responses to vaccines and often cannot tolerate small-30 molecule antivirals. The Omicron variant of concern of SARS-CoV-2 has progressively defeated anti-Spike mAbs authorized so far, paving the way to a return to COVID-19 convalescent plasma 31 32 (CCP) therapy. In this systematic review we performed a metanalysis of 6 controlled studies (including 2 randomized controlled trials; totaling 368 treated patients and 1119 control), an 33 34 individual patient data analysis of 125 case reports/series (totaling 265 patients), and a descriptive 35 analysis of 13 uncontrolled large case series without individual patient data available (totaling 358 36 patients). Our findings show a risk ratio for mortality of 0.61 in treatment with CCP versus standard of care for immunosuppressed COVID-19 patients. On the basis of this evidence, we encourage 37 initiation of high-titer CCP from vaccinees (hybrid plasma) in immunocompromised patients. 38

39 Introduction

In December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in 40 Wuhan (China)(1, 2), causing coronavirus disease 2019 (COVID-19). It rapidly spread across the 41 42 globe leading to a pandemic with currently nearly 577 million infected people worldwide and 6.4 million deaths (3). A number of treatments, including antiviral, anticoagulant and anti-inflammatory 43 agents have been tested in COVID-19 patients, with often controversial results (4). The passive 44 45 transfer of anti-SARS-CoV-2 neutralizing antibodies (nAb) from plasma of recently recovered individuals (COVID-19 convalescent plasma, CCP) to patients with severe COVID-19 was among 46 the first therapies used (5-7). Nowadays we know that such antibody-based treatment, when 47 48 administered early (within 72 hours since onset of symptoms) and with high titers of neutralizing antibodies (nAb), leads to clinical benefit (8, 9). 49

50 In spite of the marketing of monoclonal antibodies (mAbs) against COVID-19 since February 2021, 51 the high mutation rate of SARS-CoV-2 (approximately a novel variant of concern (VOC) every 6 52 months) progressively escaped most, if not all, mAbs (10). By contrast, thanks to the prompt 53 availability of CCP against emerging VOCs, CCP maintained its efficacy over time by following the ongoing Spike protein evolution. As a result, since the beginning of 2022 there has been a 54 renewed interest toward CCP use, particularly for immunocompromised patients, who are not able 55 56 to mount a sufficiently protective antibody response against the virus and have contraindications or 57 side effects from small molecule antivirals (11, 12). These patients are at higher risk for morbidity 58 and mortality from COVID-19 (13). A few controlled studies and a number of case reports and case series have shown a clinical benefit from CCP use for COVID-19 patients with hematological or 59 solid cancer or other underlying causes of immunosuppression. For such reasons, on January 2022 60 the US Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) of 61 62 CCP to include those hospitalized with impaired humoral immunity (14).

To further summarize the heterogeneous literature data on the CCP use in immunocompromised
patients, possibly identifying factors involved in more favorable outcomes, we have performed here
a systematic literature review.

66 Materials and methods

67 Search criteria

68 In this systematic review, we investigated the impact of CCP on COVID-19 mortality in patients 69 with primary (i.e., inheritable) or secondary immunosuppression (i.e., related to haematological or 70 solid cancers, autoimmune disorders or organ transplants). For this purpose, an electronic literature 71 search through the online PubMed and MEDLINE databases was initiated for articles published from January 1, 2020 to July 20, 2022, using English language as the only restriction. The Medical 72 73 Subject Heading (MeSH) and keywords used were: ("COVID-19" OR "SARS-CoV-2" OR "coronavirus disease 2019") AND ("convalescent plasma" OR "immune plasma" 74 OR 75 "hyperimmune plasma") AND ("immunosuppression" OR "immunodeficiency" OR "immunocompromised" OR "cancer" OR "transplant" OR "malignancy" OR "hematological" OR 76 "oncologic" OR "lymphoma" OR "leukemia" OR "myeloma" OR "agammaglobulinemia" OR 77 "hypogammaglobulinemia" OR "common variable immunodeficiency" OR "autoimmune 78 79 disorder"). Relevant articles and data were also identified through non-systematic searches in 80 Google Scholar and medRxiv, including abstracts of congress presentations which were not 81 published yet. We also screened the reference list of reviewed articles for additional studies not 82 captured in our initial systematic literature search. To be considered eligible for inclusion, studies 83 must include: 1) patients with primary or secondary immunosuppression with a confirmed diagnosis 84 of COVID-19; 2) CCP as a COVID-19 treatment; and 3) information on patients' outcome. To 85 perform a comprehensive analysis, the retrieved literature was grouped into three different strata, 86 according to information characteristics: 1) controlled trials underwent a quantitative analysis

(meta-analysis); 2) large case series with aggregated data underwent a descriptive analysis; and 3)
case reports and case series with individual patient data underwent a single patient analysis.

89 Articles underwent a reciprocally blind evaluation for inclusion by two assessors (J.W.S. and M.F.) 90 and disagreements were resolved by a third senior assessor (D.F.). A PRISMA flowchart for this review is available in Figure 1. The following data, when available, were searched for each case: 91 92 patient's sex and age, the underlying primary or secondary immunodeficiency, the 11-point WHO COVID-19 disease severity score (15), the need for mechanical ventilation, survival at the end of 93 94 follow-up, the number of CCP units transfused, the volume of each CCP unit, the total CCP volume 95 transfused, the antibody level (either nAb titer or anti-Spike IgG levels) and the antibody test used, 96 time from admission to CCP transfusion, time from symptom onset to CCP transfusion, rapid clinical improvement (defined as a reduction in supplemental oxygen requirements < 5 days post-97 CCP transfusion), duration of follow-up (days), need for admission to intensive care unit (ICU), 98 99 ICU length of stay (days; total and after CCP transfusion), concomitant COVID-19 antiviral 100 treatments (intravenous immunoglobulins, remdesivir, hydroxychloroquine, anti-Spike mAbs), and 101 specific immunosuppressive drugs (anti-CD20 mAbs).

102

103 Systematic review of comparative studies

We have considered both RCTs and non-RCT. Two review authors (MF, MC) independently assessed the risk of bias (ROB) of each included study following the domain-based evaluation described in the *Cochrane Handbook for Systematic Reviews of Interventions*. [Higgins, J.P., Green, S. (eds.): Cochrane Handbook for Systematic Reviews of Interventions – Version 5.1.0 [updated March 2011]. The Cochrane Collaboration <u>http://www.cochranehandbook.org</u>.].

109 Within-trial ROB was assessed, using the Cochrane ROB tool for RCTs and the ROBINS-I tool for

110 non-RCTs.[Higgins, J.P., Green, S. (eds.): Cochrane Handbook for Systematic Reviews of

111 Interventions – Version 5.1.0 [updated March 2011]. The Cochrane Collaboration http://www.cochranehandbook.org.]. The Cochrane 'Risk of bias' tool for RCTs addresses six 112 113 specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting, and other issues relating to bias. The methodological quality of observational 114 115 studies was assessed with the ROBINS-1 tool (16). This tool includes seven specific bias domains, pre-intervention and post-intervention. The domains are: (1) confounding; (2) selection of 116 117 participants; (3) classification of intervention; (4) deviation from interventions (o biases that arise 118 when there are systematic differences between the care provided to experimental intervention and 119 comparator groups, beyond the assigned interventions); (5) missing outcome; (6) measurement of 120 outcomes; (7) selection of reported result overall. For both RCTs and non-RCTs we have presented 121 our assessment of risk of bias using two 'Risk of bias' summary figures: 1) a summary of bias for 122 each item across all studies; and 2) a cross-tabulation of each trial by all the 'Risk of bias' items.

123

124 *Effect of intervention*

Measures of treatment effect were risk ratio (RR) and mean difference (MD). The study weight was calculated using the Mantel-Haenszel method. We assessed statistical heterogeneity using t^2 , Cochran's Q and I^2 statistics (17). The I^2 statistic describes the percentage of total variation across trials due to heterogeneity rather than sampling error. In the case of no heterogeneity (I^2 =0), studies were pooled using a fixed-effects model. Where values of I^2 were >0, a random-effects analysis was undertaken.

131

132 'Summary of findings' tables

For the outcome mortality, we used the principles of the GRADE system to assess the quality of the body of evidence associated with specific outcomes and constructed 'Summary of findings' tables using REVMAN 5.4 (18, 19). These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of

available data for the main outcomes. The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE approach, which defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The certainty of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias.

143

144 Statistical analysis of individual patient data

In the descriptive statistics of individual patient data, continuous variables were reported as mean (\pm SD) or median (range) as appropriate according to distribution, while categorical variables were reported as numbers and percentages.

An exploratory analysis on the main theme was done on the mortality after discretizing the total volume, as <= 200 ml to 1800 ml with serial increases of 200 ml. Then, a breakpoint at 600 ml of CCP was tentatively posed, allowing to compare the mortality when the CCP was under or over the level by Fisher exact test.

The basic model consisted in a logistic regression using mortality as dependent variable, and total volume as predictor. The CCP total volume was expressed in units of 100 ml ("totvol100"), for ease of interpretation. The potential additive independent effects of "Age", "Sex", "Time from admission to transfusion", "Rapid improvement (within 5 days)", "ICU length of stay", "Steroids", "Remdesivir", "(Hydroxy)chloroquine", "Antibiotics", "Anti-CD20", and "Category" were evaluated.

In power analysis, the total sample size was calculated in order to detect an experimental-group proportion of 0.06 as death rate, with the control-group proportion of 0.08, assuming a one-sided hypothesis test with a 5% significance level, focusing a desired power of 80%, and if both groups

(treated and untreated) had the same number of observations. This would correspond to theprevention of 25% of the basal deaths, or a risk ratio (RR) of 0.75.

163 Stata 17.0 was used for all statistical calculations.

164

165 **Results**

The literature search yielded 461 eligible studies, of which 6 controlled trials (2 randomized trials (20, 21) and 4 cohort studies (22-25)) were selected for meta-analysis, 13 uncontrolled large case series without individual patient data but totaling 358 patients were selected for descriptive analysis (26-38), and 125 case reports/series totaling met the eligibility criteria for individual patient data analysis, providing information on 265 patients (32, 39-162). Reference (32) was included in both the descriptive analysis and the individual patient data analysis because individual patient data were available only for a subgroup of patients.

In the metanalysis of the 6 controlled trials (totaling 368 patients treated with CCP and 1168 controls), the main findings are summarized in Table 1. As shown in Figure 2 the level of evidences was generally low because of a high ROB (Figure 2). Despite this, there is a high level of concordance among study outcomes, with a risk difference of -0.12, and a risk ratio of 0.61 (Figure 3).

The demographic and clinical characteristics of the individual patient data are summarized in Table 3 and are available individually in Supplementary Table 1. The median age was 55 years (range 1-88 years). The male/female ratio was 1.5 (161 males and 105 females). Mean WHO disease severity score was 4.4, with approximately one quarter of patients (51/218) being in ICU on mechanical ventilation. The reported mortality rate was 11.6% (31/265). Forty-seven patients (17.7%) had a primary immunosuppression, mostly agammaglobulinemia (20/47, 42.6%) or common variable immunodeficiency (22/47, 4.8%). The remaining 219 patients had secondary immunosuppression,

185 related to hematological malignancies (134/219, 61.2%), solid cancers (6/219, 2.7%), solid organ 186 transplants (65/219, 29.7%), autoimmune disorders (12/219, 5.5%) or other chronic infectious 187 disease (2/219, 0.9%) (see Table 1). Regarding treatments, the majority of patients (142/265, 188 53.4%) received steroids as part of the anti-COVID-19 therapy, while 41.7% of them (111/265) 189 received remdesivir and 47% antibiotics (125/265). Approximately one fifth of patients (45/265) 190 also received intravenous immunoglobulin, while a minority of them (11/265, 4.1%) were treated 191 with anti-Spike mAbs: interestingly, in 7 of such cases (7/11, 63.6%), CCP was given as rescue 192 therapy after mAb failure and all 7 patients survived. Nearly 20% of patients (47/265) were under 193 chemotherapy, which in the majority of the cases (35/47, 74.5%) included anti-CD20 mAbs (i.e., 194 rituximab or obinutuzumab), responsible for prolonged B-cell depletion and impaired humoral 195 immune responses. Table 4 summarizes the CCP treatment-related data. The mean number of CCP units transfused per patient was 2.3 (\pm 1.7), while the mean cumulative CCP volume transfused per 196 197 patient was 460 ml (\pm 372 ml). Unfortunately, it was not possible to calculate the mean nAb titer or 198 to correlate the patients' outcome with nAb titers due to the wide heterogeneity of tests used (virus 199 neutralization or high-throughput serology). No adverse reactions to CCP were reported. The 200 median time between symptom onset and CCP therapy was 17 days (range 1-132 days), while the 201 median time between hospital admission and CCP therapy was 11 days (0-120 days). The median 202 follow-up period of the patients included in this single patients' analysis was 19 days (range 4-263 203 days; data available for 69 patients). Fifty-six percent of the 114 evaluable patients had a rapid (< 5204 days) clinical improvement following CCP transfusion. Thirty-one death events were observed (22 205 male and 9 females). On 126 cases where mortality and total volume were known, 7 death events 206 were found (6 males and 1 female). These data are reported in Table 5 and Figure 4. The 7 death 207 events were observed in the group of 92 patients where the CCP total volume did not exceed 600 208 ml. The comparison of the mortality when the CCP was under (7 events, 92 patients) or over this 209 level (zero events, 34 patients), however, was not significant. The coefficients of the basic logistic model are reported in Table 6. No inferential significance was obtained. However, the coefficient of 210

211 "totvol100" had a negative sign, suggesting a decrease of approximately 5% of the starting 212 probability of death for each 100 ml unit added. If the dose-response effect was real, with 600 ml of 213 CCP the mortality reduction would be 26.64%, with 1200 ml would be 46.48%, and with 1800 ml would be 61.12%. Of course, this would need confirmation by a more extended number of 214 215 observations. Adding to the basic model the above listed covariates, "Age", "Mechanical 216 Ventilation", "Category=autoimmune", "Category=solid cancer", and "Anti-Spike mAbs" appeared 217 to predict a significant increase of mortality. By logistic model, the evaluation of the role of anti-218 CD20 was impossible since anti-CD20 = "yes" predicted failure (survival) perfectly (nobody died if 219 treated with anti-CD20 if CCP total volume information was available). This happened with "Rapid 220 improvement", "(Hydroxy)chloroquine", "Category=common", "Category=humoral" as well. In 221 contrast, failure to receive steroids or antibiotics predicted survival perfectly; in other words, deaths 222 were found only in treated people.

The total sample size calculated by power analysis for RR = 0.75 was 4,024, for RR = 0.5 was 870.

224

225 **Discussion**

Several scientific societies (e.g., ECIL-9 (163), CDC/IDSA(164) and AABB (165) have recently
revised their guidelines to recommend usage of CCP in immunocompromised patients, expecially
after Omicron sublineages progressively defeated mAb therapies authorized so far.

The hypothesis of a significant beneficial effect of CCP on mortality in immunocompromised patients cannot be definitively demonstrated with the present data, but very strong elements support its efficacy. The efficacy of antibody-based therapies for immunocompetent individuals is predicated on early administration with sufficient dosage (166). This principle was validated by the experience of CCP in COVID-19 (9). While several immunocompromised cases have been treated with CCP derivatives (hyperimmune immunoglobulins) (167), CCP is superior in turnaround times

235 and inclusion of classes other than IgG (168). However, we note that the immunosuppressed 236 patients in this study were treated relatively late after the initial symptoms (17 d) and hospital 237 admission (11 d) and yet our analysis suggests a benefit for CCP. For life-threatening COVID-19 238 the pathogenesis involves exuberant tissue-damaging inflammatory responses that follow an initial 239 viral phase. Antibody-based therapies function primarily as antiviral agents and are much less likely 240 to be affected in individuals who are in the inflammatory phase. However, immunocompromised 241 individuals are generally unable to mount strong antibody or inflammatory responses and often 242 cannot clear SARS-CoV-2. Hence, immunosuppressed patients represent a biologically different 243 population from the immunocompetent population where antibody-based therapies may retain 244 efficacy late into the course of disease.

245 The efficacy of CCP in immunosuppressed patients that had reported symptoms for weeks or 246 months paves the way to the hypothesis that CCP retains clinical efficacy until the recipient is 247 seronegative and there is no irreversible parenchymal damage. The recently reopened CCP arm of 248 the REMAP-CAP randomized controlled trial in UK will specifically target immunocompromised 249 patients in ICU focusing on CCP from vaccinated donors (so-called VaxCCP or "hybrid" plasma) 250 (169). While most studies reported in this systematic review used CCP from unvaccinated donors 251 (with a few exceptions (122, 149)), it is noteworthy that VaxCCP is nowadays widely available 252 from regular donors, retains higher nAb titers and efficacy against most Omicron sublineages than 253 standard CCP (170).

254

255 **COI statement**: We declare we don't have any conflict of interest related to this manuscript.

Data availability statement: This secondary research did not generate original data, which remain
available at the cited references.

258 Acknowledgements: We are grateful to Dr. Thomas Hueso who contributed to data analysis.

Figure 1

PRISMA flow chart for the current study.



Figure 2

Risk of bias summary for the controlled studies: review authors' judgements about each risk of bias (ROB) item according to ROBIN-1 tool for each included study. Left: RCTs, analysis according to ROB assessment tool. Right Non-RCTs.



Figure 3

Risk difference (top panel) and risk ratio (bottom panel) for mortality in randomized or cohort controlled studies included in this systematic review.

	CP		Contr	ol		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
1.1.1 RCT							
Bar	1	15	5	17	4.8%	-0.23 [-0.48, 0.02]	
Muller-Tidow	12	68	15	65	14.8%	-0.05 [-0.19, 0.08]	
Subtotal (95% CI)		83		82	19.6%	-0.11 [-0.27, 0.05]	
Total events	13		20				
Heterogeneity: Tau ² =	= 0.00; Ch	i ^z = 1.42	2, df = 1 (P = 0.2	3); I ^z = 30	%	
Test for overall effect	: Z = 1.34 ((P = 0.1	8)				
1.1.2 cohort							
Biernat	3	23	9	22	5.0%	-0.28 [-0.53, -0.03]	
Cristelli	13	58	28	116	15.6%	-0.02 [-0.15, 0.12]	
Hueso	13	61	29	76	12.6%	-0.17 [-0.32, -0.02]	
Thompson	19	143	204	823	47.2%	-0.12 [-0.18, -0.05]	T
Subtotal (95% CI)		285		1037	80.4%	-0.12 [-0.19, -0.04]	•
Total events	48		270				
Heterogeneity: Tau ² =	= 0.00; Ch	i ² = 4.26	6, df = 3 (P = 0.2	4); I² = 30	%	
Test for overall effect	: Z = 3.07 ((P = 0.0	02)				
Total (05% CI)		260		4440	400.0%	0 44 5 0 47 0 051	
Total (95% CI)		208		1119	100.0%	-0.11 [-0.17, -0.05]	•
I otal events	- 0.00. OF	2 - 6 70	290		0.17 - 40	07	
Heterogeneity: Lau-=	= 0.00; Cn • 7 = 0.00;	r= 5.78 (n = 0.0	o, αī = 5 (004)	P = 0.3	3); 1* = 13	%	-1 -0.5 0 0.5 1
Test for overall effect	:∠=3.80) ¥	(P = 0.0	001) 204 -46-	4 (0 -	0.000 17-	000	Favours CP Favours control
rest for subgroup all	ierences:	Chi= t	J.01, dr=	1 (P =	0.93), F=	0%	
	CP		Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	CP Events	Total	Contr Events	ol Total	Weight	Risk Ratio M-H. Random, 95% CL	Risk Ratio M-H. Random, 95% Cl
Study or Subgroup	CP Events	Total	Contr Events	ol Total	Weight	Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar	CP Events	Total	Contr Events	ol <u>Total</u>	Weight	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow	CP Events 1	Total 15 68	Contr Events	rol <u>Total</u> 17 65	Weight	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51]	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI)	CP Events 1 12	Total 15 68 83	Contr Events 5 15	rol Total 17 65 82	Weight 1.7% 14.9% 16.6%	Risk Ratio M-H, Random, 95% Cl 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56]	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events	CP Events 1 12	Total 15 68 83	Contr Events 5 15 20	rol <u>Total</u> 17 65 82	Weight 1.7% 14.9% 16.6%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56]	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity Tau ²	CP Events 1 12 13 = 0.16: Ch	Total 15 68 83	Contr Events 5 15 20 7 df = 1 (rol Total 17 65 82 P = 0.2	Weight 1.7% 14.9% 16.6%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56]	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	CP Events 1 12 13 = 0.16; Ch ; Z = 1.03;	Total 15 68 83 F = 1.23 F = 0.3	Contr Events 5 15 20 7, df = 1 (0)	rol Total 17 65 82 P = 0.2	Weight 1.7% 14.9% 16.6% 6); I² = 21	Risk Ratio M-H, Random, 95% CI 0.23 (0.03, 1.73) 0.76 (0.39, 1.51) 0.61 (0.24, 1.56)	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	CP Events 1 12 13 = 0.16; Ch ; Z = 1.03	Total 15 68 83 (P = 0.3	Contr Events 5 15 20 7, df = 1 (0)	rol <u>Total</u> 17 65 82 P = 0.2	Weight 1.7% 14.9% 16.6% 6); I² = 21	Risk Ratio M-H, Random, 95% CI 0.23 (0.03, 1.73) 0.76 (0.39, 1.51) 0.61 (0.24, 1.56) %	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort	CP Events 1 12 13 = 0.16; Ch ; Z = 1.03 (Total 15 68 83 (P = 0.3	Contr Events 5 15 20 7, df = 1 (0)	rol <u>Total</u> 17 65 82 P = 0.2	Weight 1.7% 14.9% 16.6% 6); I² = 21	Risk Ratio M-H, Random, 95% CI 0.23 (0.03, 1.73) 0.76 (0.39, 1.51) 0.61 (0.24, 1.56) %	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 (3	Total 15 68 83 (P = 0.3 23	Contr Events 5 15 20 7, df = 1 (0) 9	rol <u>Total</u> 17 65 82 P = 0.2 22	Weight 1.7% 14.9% 16.6% 6); I ^z = 21 5.1%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 3 13	Total 15 68 83 (P = 0.3 (P = 0.3 23 58	Contr Events 5 15 20 7, df = 1 (0) 9 28	rol 17 65 82 P = 0.2 22 116	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 3 13 13 13 13	Total 15 68 83 F = 1.2; (P = 0.3 23 58 61	Contr Events 5 15 20 7, df = 1 (0) 9 28 28 29	rol <u>Total</u> 17 65 82 P = 0.2 22 116 76	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 13 13 13	Total 15 68 83 F ² = 1.2; (P = 0.3 (P = 0.3 58 61 143	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204	rol <u>Total</u> 17 65 82 P = 0.2 22 116 76 823	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI)	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 3 13 13 13 13 13	Total 15 68 83 (P = 0.3 (P = 0.3 58 61 143 285	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204	Total 17 65 82 P = 0.2 22 116 76 823 1037	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 19 48	Total 15 68 83 (P = 0.3 23 58 61 143 285	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 29 204 270	Total 17 65 82 P = 0.2 22 116 76 823 1037	Weight 1.7% 14.9% 16.6% 6); I² = 21 5.1% 20.6% 21.8% 35.9% 83.4%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² =	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 13 19 48 = 0.02; Ch	Total 15 68 83 (P = 0.3 (P = 0.3 23 58 61 143 285 P = 3.6	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 270 7, df = 3 (Total 17 65 82 P = 0.2 116 76 823 1037 P = 0.3	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ² = 18	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 13 19 48 = 0.02; Ch : Z = 3.05	Total 15 68 83 (P = 0.3 (P = 0.3 23 58 61 143 285 (P = 0.0 (P = 0.0	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 270 7, df = 3 (02)	Total 17 65 82 P = 0.2 116 76 823 1037 P = 0.3	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ² = 18	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83] %	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 19 48 = 0.02; Ch : Z = 3.05	Total 15 68 83 (P = 0.3 (P = 0.3 23 58 61 143 285 (P = 0.0 (P = 0.0	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 270 7, df = 3 (02)	rol Total 17 65 82 P = 0.2 116 763 763 703 1037 P = 0.3	Weight 1.7% 14.9% 16.6% 6); I ^z = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ^z = 18	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.56 [0.32, 0.83] 0.60 [0.43, 0.83] %	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% CI)	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 19 48 = 0.02; Ch : Z = 3.05	Total 15 68 83 1 ² = 1.2; (P = 0.3 23 58 61 143 285 (P = 0.0 368	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 270 7, df = 3 (02)	Total 17 65 82 P = 0.2 116 763 1037 P = 0.3 1119	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ² = 18 100.0%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83] % 0.61 [0.47, 0.80]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% CI) Total events	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 19 48 = 0.02; Ch : Z = 3.05 61	Total 15 68 83 (P = 0.3 (P = 0.3 23 58 61 143 285 (P = 0.0 368	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 270 7, df = 3 (02) 290	Total 17 65 82 P = 0.2 116 76 823 1037 P = 0.3 1119	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ² = 18 100.0%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.56 [0.32, 0.98] 0.60 [0.43, 0.83] % 0.61 [0.47, 0.80]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% CI) Total events Heterogeneity: Tau ² =	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 19 48 = 0.02; Ch : Z = 3.05 61 = 0.00; Ch	Total 15 68 83 12 = 1.2; (P = 0.3 23 58 61 143 285 (P = 0.0 368 (P = 0.0 368 (P = 5.04)	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 29 204 270 7, df = 3 (02) 290 4, df = 5 (rol <u>Total</u> 17 65 82 P = 0.2 116 763 1037 P = 0.3 1119 P = 0.4	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ² = 18 100.0% 1); I ² = 1%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83] % 0.61 [0.47, 0.80]	Risk Ratio M-H, Random, 95% CI
Study or Subgroup 1.1.1 RCT Bar Muller-Tidow Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect 1.1.2 cohort Biernat Cristelli Hueso Thompson Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect Total events Heterogeneity: Tau ² = Total events Heterogeneity: Tau ² = Test for overall effect	CP Events 1 12 13 = 0.16; Ch : Z = 1.03 13 13 13 13 19 48 = 0.02; Ch : Z = 3.05 61 = 0.00; Ch : Z = 3.64	Total 15 68 83 12 (P = 0.3 23 58 61 143 285 (P = 0.0 368 (P = 0.0 (P = 0.0 (P = 0.0) (P = 0.0)	Contr Events 5 15 20 7, df = 1 (0) 9 28 29 204 29 204 270 7, df = 3 (02) 290 4, df = 5 (003)	rol <u>Total</u> 17 65 82 P = 0.2 22 116 763 823 1037 P = 0.3 1119 P = 0.4	Weight 1.7% 14.9% 16.6% 6); I ² = 21 5.1% 20.6% 21.8% 35.9% 83.4% 0); I ² = 18 100.0% 1); I ² = 1%	Risk Ratio M-H, Random, 95% CI 0.23 [0.03, 1.73] 0.76 [0.39, 1.51] 0.61 [0.24, 1.56] % 0.32 [0.10, 1.03] 0.93 [0.52, 1.65] 0.56 [0.32, 0.98] 0.54 [0.35, 0.83] 0.60 [0.43, 0.83] % 0.61 [0.47, 0.80]	Risk Ratio M-H, Random, 95% CI

Figure 4

Mortality under different levels of CCP treatment in 265 individual patients, as total volume from <= 200 ml to >1800 ml. Blue bars: death incidence. Orange bars: number of patients at risk at each level of CCP.



Figure 5

Predicted probability of death at various levels of CCP total volume, after logistic regression, basic model. The CCP total volume ("totvol100") is expressed as 100 ml units. The large confidence intervals pinpoint the need for a confirmation by a more extended number of observations.



Table 1

Summary of findings for the 6 controlled studies included in the metanalysis.

Patient or population: Immunocompromised patients

Settings: Hospitalized patients with COVID-19

Intervention: COVID-19 convalescent plasma (CCP)

Comparison: standard of care (SOC)

eompanisoni s	undur d Or					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	risk	()) // ())	(studies)	(GRADE)	
	Controls (standard of care)	Intervention (convalescent plasma)				
All cause mortality						
- All studies (RCTs and non-RCTs)	259 per 1000	177 per 1000 (from 136 to 232)	RR 0.81 (95% CIs, -0.47 to 0.80)	1487 patients (6 trials, 2 RCTs and 2 non-RCTs)	⊕⊕⊖⊖ low (downgraded for serious ROB)	Mortality was observed more commonly among SOC recipients compared to CCP
-RCTs only	243 per 1000	148 per 1000 (from 58 to 379)	RR 0.61 (95 % CIs, 0.24/1.56)	165 participants (2 RCTs)	⊕⊕⊖⊖ low (downgraded for ROB and imprecision due to the low number of participants)	It is unclear if CCP reduces mortality compared to SOC
-Cohort studies only	260 per 1000	156 per 1000 (from 112 to 216	RR 0.60 (95 % CIs, 0.43/0.83)	1322 participants (4 trials)	⊕⊕⊖ low (downgraded for serious ROB)	Mortality was observed more commonly among SOC recipients compared to CCP. In sensitivity analysis, the effect size after exclusion of Thompson in subgroup of

			cohort studies is
			no longer s.s.
			(RR 0.63, 95 %
			CIs 0.38/1.05,
			p=0.08; RD -
			0.13; 95 % CIs,
			-0.27/0.01;
			p=0.07))

*The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; MD: Mean Difference; RR: risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

RR, risk ratio; CIs, confidence intervals; ROB, risk of bias.

Summary of uncontrolled studies with aggregated results on the CCP use in immunocompromised patients.

First author,	Population	Diagnosis	COVID-19	CCP regimen	Days	Previous/concomitant	Outcome	Notes/Conclusions
reference					between	therapies		
					symptoms			
					and CCP			
Betrains (28)	5 F, median age	5 NHL	Severe	4 high-titer	N/A	1 steroids, 3 HCQ, 1	Increase in nAb	Patients with B-cell-
	37 y (range 19-67		COVID-19	(≥1:160 VNT)		antibiotics, 2	titer following	depleted lymphomas are
	y)			CCP units		remdesivir	ССР	ideal candidates for CCP
							Overall	therapy
							mortality rate	
							1/5 (20%)	
Gharbharan	25 (15 M, 10 F),	12 NHL	19 severe	21 patients 1	Median 26 d	N/A	Overall	24/25 anti-CD20 therapy.
(26)	median age 53 y	1 AL	COVID-19,	CCP unit, 4	(IQR 15-34 d)		mortality rate	The CCP benefit in B-cell
	(IQR 44-66 y)	8 AID	6 mild-	patients 2			4/25 (16%)	depleted patients is present
		2 CLL	moderate	CCP units				regardless of symptom
		1 MS	COVID-19					duration.
		1 AGG						
Greenbaun(27)	44 (M 25, 19 F),	17 SC	Severe	42 patients 1	N/A	32 remdesivir, 20	Overall	Shorter time from COVID-

	median age 60	27 HM	COVID-19	CCP unit, 2		tocilizumab, 11	mortality 12/44	19 diagnosis to CCP
	(range 37-48 y)			patients 2		steroids, 1 anakinra	(27.3%)	administration (\leq 3 days)
				CCP units				was associated with better
								survival
Hueso(38)	17 (12 M, 5 F),	11 NHL	WHO score 4-	CCP units	Median 56 d	8 steroids, 5 HCQ, 4	Rapid viral	15/17 previous treatment
	median age 58 y	3 CLL	7	≥1:40 (VNT)	(range 7-83 d)	tocilizumab, 3	clearance	with anti-CD20 therapy.
	(range 35-77 y)	1 WM		or > 5.6		remdesivir, 2 antivirals	following CCP	CCP is a promising therapy
		1 CVID		(ELISA)			Overall	for COVID-19 B-cell
		1 MS					mortality rate	depleted patients
							1/15 (6.7%)	
Jasuja(29)	22 (N/A)	22 KTR	N/A	N/A	N/A	HCQ, steroids,	Overall	CCP was associated with no
						antibiotics, remdesivir,	mortality rate	clinical benefit in KTR
						tocilizumab	7/22 (31.8%)	
Jeyaraman(30)	33 (23 M, 10 F),	18 NHL	Severe	CCP units	Median 4 d	HCQ, steroids,	Overall 42.day	Study with methodological
	median age 62 y	4 AL	COVID-19	>1:640	(range 2-25 d)	antibiotics, remdesivir,	mortality rate	limitations (retrospective
	(range 7-80 y)	7 MM		18 patients 1		tocilizumab	15/33 (45.5%).	case series)
		2 MPD		CCP unit, 15			No mortality	
		2 MDS		patients 2			difference	
				CCP units			between early	
							(<7 days)	

							versus late CCP	
							transfusion	
Levy (31)	50 (N/A)	23 NHL	40	N/A	N/A	Steroids, remdesivir	Overall	CCP was associated with no
		9 MM	severe/critical				mortality rate	clinical benefit
		8 CLL	COVID-19; 10				16/50 (32%)	
		1 MPD	mild/moderate					
		6 AL	COVID-19					
		2 MDS						
		1 HCL						
Ljunquist (32)	28 (13 M, 15 F),	13 HM	Severe	76 CCP units	Median 26 d	23 steroids, 18	Overall 30 days	50% (14/28) of patients
	median age 56	5 SOT	COVID-19	transfused	(range 6-68 d)	remdesivir	mortality rate	received rituximab.
	(range 16-84 y)	2 PI		(median nAb			6/28 (21.4%)	Data not conclusive.
				titer 1:141).				
				21 patients				
				received 3				
				CCP units				
Magyari (33)	20 (13 M, 7 F),	10 NHL,	18 moderate	Median 4	Median 13.5	17 patients received	No COVID-19	Anti-CD20 therapy in 13/20
	median age 56 y	1 MM	COVID-19	CCP units	d (range 3-44	concomitant	related deaths	patients (65.0%). Clinical
	(range 27-76 y)	4 CLL	(WHO score 4-	(range 1-15	d)	remdesivir, 20	were recorded	benefit of early combined
		4 AL	5)	units)		steroids, 9 antivirals		administration of remdesivir

		1 MPD	2 severe					and CCP
			COVID-19					
			(WHO score 8-					
			9)					
Tremblay (34)	24 (14 M, 10 F),	5 NHL	Severe	High titer	N/A	16 HCQ, 15	Overall	Clinical benefit of CCP
	median age 69 y	4 MM	COVID-19	(≥1:320) CCP		antibiotics, 2	mortality rate	when administered early in
	(range 31-88 y)	2 AL		units		remdesivir, 1	41.2% (10/24)	the COVID-19 disease
		1 HL				tocilizumab		course
		1 MPD						
		1 CLL						
		10 SC						
Rodionov (35)	14 (7 M, 7 F),	8 SOT	Median WHO	Titer ≥1:40	N/A	N/A	Overall	Immunosuppressed patients
	median age 65 y	4 HSCT	score 5 (range	CCP units			mortality 2/14	are candidates for CCP
	(IQR 58-70 y)	2 HM	4-6)	(VNT)			(14.3%).	treatment
				1 patient 1			8/14 (57.0%)	
				CCP unit, 2			showed clinical	
				patients 2			improvement	
				CCP units, 11			on day 5 after	
				patients 3			ССР	
				CCP units				
1	1							

Sait (36)	44 (N/A)	SOT	Median WHO	N/A	N/A	Steroids, remdesivir,	Overall	The use of CC is
			score 4 (IQR 3-			antibiotics	mortality 3/44	encouraged in SOT
			5)				(6.8%)	inpatients
Weinbergerova	32 (19 M, 13 F),	10 NHL	16/32 (50.0%)	2 units high	N/A	Steroids, remdesivir	3/32 (9.4%)	Early COVID-19 treatment
(37)	median age 57.7 y	10 AL	severe	titer (<u>≥</u> 1:160)				with remdesivir + high titer
	(range 25-86 y)	6 MM	COVID-19	CCP units				CCP is effective in
		3 CLL						hematological patients
		2 MPD						
		1 AID						
					1			

Abbreviations: AL, acute leukemia; AID, autoimmune disorder; AGG, agammaglobulinemia; CCP, COVID-19 convalescent plasma; CLL, chronic lymphocytic leukemia; CVID, common variable immune deficiency; d, days; ELISA, enzyme-linked immunosorbent assay; F, females; HCL, hairy cell leukemia; HCQ, hydroxychloroquine; HL, Hodgkin's lymphoma; HM, hematological malignancy; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; KTR, kidney transplant recipients; M, males; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPD, myeloproliferative disorders; MS, multiple sclerosis; N/A, not available; nAb, neutralizing antibody; NHL, non-Hodgkin's lymphoma; PI, primary immunodeficiency; SC, solid cancers; SOT, solid organ transplant; VNT, viral neutralization test; WHO, World Health Organization; WM, Waldenstrom macroglobulinemia; y, years;.

Demographic and clinical characteristics of the 265 patients included in the individual patients' analysis.

Parameters	Results
Median age, years (range)	55 (1-88)
Males/females (n)	161/105
Male/female (ratio)	1.5
Mortality, n (%)	31/265 (11.6)
COVID-19 severity	
- WHO disease severity score, mean $(\pm SD)^1$	4.4 (<u>+</u> 1.8)
- Mechanical ventilation, n (%)	51/218 (23.4)
- ICU length of stay, median days (range) ²	33 (6-271)
Condition, n (%)	
- Primary immunosuppression	47/265 (17.7)
Agammaglobulinemia	20/47 (42.6)
Common variable immunodeficiency	22/47 (46.8)
Others	5/47 (10.6)
- Secondary immunosuppression	219/265 (82.3)

Hematological malignancies	134/219 (61.2)
Non-Hodgkin's lymphoma	75/134 (56.0)
Chronic lymphocytic leukemia	17/134 (12.7)
Multiple myeloma	5/134 (3.7)
Myelodysplastic syndrome	2/134 (1.5)
Acute leukemia	13/134 (9.7)
Myeloproliferative disorders	3/134 (2.2)
HSCT	4/134 (3.0)
PHLH	1/134 (0.7)
Not specified	14/134 (10.4)
Solid cancers	6/219 (2.7)
Sarcoma	1/6 (16.7)
Wilm's tumor	1/6 (16.7)
Thymoma	2/6 (33.2)
Lung cancer	1/6 (16.7)
Prostate cancer	1/6 (16.7)
Solid organ transplants	65/219 (29.7)

Kidney	43/65 (66.1)
Liver	14/65 (21.5)
Heart	7/65 (10.8)
Not specified	1/65 (1.5)
Autoimmune disorders	12/219 (4.5)
Systemic lupus erythematosus	2/12 (16.7)
Sjogren syndrome	1/12 (8.3)
Rheumatoid arthritis	2/12 (16.7)
MCVD	2/12 (16.7)
Others	5/12 (41.7)
Infective	2/219 (0.9)
HIV	2/2 (100)
Concomitant therapies, n (%)	
- Remdesivir	111/265 (41.7)
- IVIG	45/265 (16.9)
- Hydroxychloroquine	40/265 (15.0)
- Steroids	142/265 (53.4)

-	Anti-SARS-CoV-2 monoclonal antibodies	11/265 (4.1)
	Casirivimab + imdevimab	3/11 (27.3)
	Bamlanivimab	4/11 (36.4)
	Bamlanivimab + etesivimab	3/11 (27.3)
	Not specified	1/11 (9.0)
-	Antibiotics	125/265 (47.0)
-	Other therapeutics ³	25/265 (9.4)
-	Chemotherapy	47/265 (17.7)
	Anti-CD20 monoclonal antibodies ⁴	35/47 (74.5)
	CAR-T	3/47 (6.4)
	Others	9/47 (19.1)
-	Immunosuppressive agents ⁵	11/265 (4.1)

Abbreviations: SD, standard deviation; ICU, intensive care unit; HSCT, hematopoietic stem cell transplantation; MCVD, mixed collagen vascular disorder; IVIG, intravenous immunoglobulin; LMWH, low molecular weight heparin; Chimeric Antigen Receptor T-cell therapies; PHLH, primary hemophagocytic lymphohistiocytosis.

¹Data available in 40 patients.

²Data available in 27 patients.

³Including protease inhibitors, antivirals, anti-IL-1 and anti-IL-6 drugs.

⁴Rituximab or obinutuzumab.

⁵Azathioprine, tacrolimus, methotrexate, mycophenolate, infliximab.

COVID-19 convalescent plasma treatment-related data in 265 individual patients.

Parameters	Information available for no. patients	Results
CCP transfused units, mean $(\pm SD; range)^1$	153	2.3 (<u>+</u> 1.7; 1-11)
CCP total transfused volume (ml) ²	126	460 (<u>+</u> 372.0; 200-1800)
Days between symptom onset and CCP therapy, median (range) ³	188	17 (1-132)
Days between hospital admission and CCP therapy, median (range) ⁴	101	11 (0-120)
Post-CCP rapid improvement in oxygen supplementation (≤ 5 days), n (%)	114	64/114 (56.1)

Mortality under different levels of CCP treatment, as total volume from $\leq 200 \text{ ml}$ to $\geq 1800 \text{ ml}$. Seven death events (5.56%) were observed on 125 patients with available CCP total volume information.

Total Volume	Mortality	Patients
<= 200	0	19
>200-400	3	43
>400-600	4	29
>600-800	0	12
>800-1000	0	12
>1000-1200	0	1
>1200-1400	0	0
>1400-1600	0	4
>1600-1800	0	4
>1800	0	1
Total	7	125

Logistic regression, table of coefficients. Mortality was the dependent variable, CCP total volume was the predictor. The CCP total volume was expressed in units of 100 ml ("totvol100"). Number of obs = 125, log likelihood = -26.896492, LR chi2(1) = 0.28, P = 0.5994, Pseudo R2 = 0.0051.

Mortality	Coefficient	Std. err.	Z	Р	95% conf. interv	al
totvol100	-0.0551	0.1156	-0.48	0.634	-0.2818 (0.1716
_cons	-2.5370	0.6998	-3.63	0.000	-3.9086 -2	L.1654

References

- 1. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. *Bmj.* 2020;368:m1036.
- 2. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *International journal of epidemiology*. 2020;49(3):717-26.
- 3. World Health Organization (WHO). Coronavirus disease (COVID-19). Accessed July 10, 2022. Available at: <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</u>.
- 4. WHO. Therapeutics and COVID-19: living guideline. Accessed online at <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4</u> on August 1, 2022.
- 5. Casadevall A, and Pirofski L-a. The convalescent sera option for containing COVID-19. *The Journal of clinical investigation*. 2020;130(4).
- 6. Franchini M, Focosi D, Corsini F, and Cruciani M. Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews. *Diagnostics*. 2021;11(9):1663.
- 7. Franchini M, Liumbruno GM, Piacentini G, Glingani C, and Zaffanello M. The Three Pillars of COVID-19 Convalescent Plasma Therapy. *Life (Basel, Switzerland)*. 2021;11(4).
- 8. Focosi D, and Franchini M. COVID-19 convalescent plasma therapy: hit fast, hit hard! . *Vox sanguinis.* 2021.
- 9. Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, et al. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. *Clinical microbiology reviews*. 2022:e0020021.
- 10. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, and Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *The Lancet Infectious Diseases*. 2022;22:00311-5.
- 11. Focosi D, and Franchini M. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. *Expert review of vaccines.* 2021:1-8.
- 12. Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. *Transfusion*. 2021;61(8):2503-11.
- 13. Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, and Palmieri C. Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2022;5(5):e2210880.
- 14. US Food and Drug Administration (FDA). Clinical memorandum Re: EUA 26382. Product: COVID-19 Convalescent Plasma. Issued on December 27, 2021 at https://www.fda.gov/media/141477/download.
- 15. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis.* 2020;20(8):e192-e7.
- 16. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *Bmj.* 2016;355:i4919.
- 17. Higgins JP, Thompson SG, Deeks JJ, and Altman DG. Measuring inconsistency in meta-analyses. *Bmj.* 2003;327(7414):557-60.
- 18. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
- 19. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, and Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? *Bmj.* 2008;336(7651):995-8.
- 20. Bar K, Shaw P, Choi G, Aqui N, Fesnak A, Yang J, et al. A Randomized, Controlled Study of Convalescent Plasma for Individuals Hospitalized with COVID-19 Pneumonia. *The Journal of clinical investigation*. 2021;131(24):e155114.

- 21. Müller-Tidow C, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, et al. *European Hematology Association*. Vienna; 2022.
- 22. Biernat MM, Kolasińska A, Kwiatkowski J, Urbaniak-Kujda D, Biernat P, Janocha-Litwin J, et al. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. *Viruses*. 2021;13(3).
- 23. Cristelli MP, Junior DML, Viana LA, de Andrade LGM, Martins SBS, Dreige YC, et al. Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis. *Transplantation.* 2021.
- 24. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA oncology.* 2021.
- 25. Hueso T, Godron AS, Lanoy E, Pacanowski J, Levi LI, Gras E, et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. *Leukemia*. 2022;36(4):1025-34.
- 26. Gharbharan A, GeurtsvanKessel CH, Jordans CCE, Blaauw M, van der Klift M, Hassing RJ, et al. Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2021.
- 27. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, et al. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. *Frontiers in immunology*. 2021:675-9.
- 28. Betrains A, Godinas L, Woei AJF, Rosseels W, Van Herck Y, Lorent N, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. *British journal of haematology*. 2021;192(6):1100-5.
- 29. Jasuja S, Sagar G, Bahl A, and Verma S. COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience. *International journal of nephrology*. 2021;2021:3129411.
- 30. Jeyaraman P, Agrawal N, Bhargava R, Bansal D, Ahmed R, Bhurani D, et al. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2021:103075.
- 31. Levy I, Lavi A, Zimran E, Grisariu S, Aumann S, Itchaki G, et al. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. *Leukemia & lymphoma*. 2021;62(14):3384-93.
- 32. Ljungquist O, Lundgren M, Iliachenko E, Månsson F, Böttiger B, Landin-Olsson M, et al. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. *Infectious diseases (London, England)*. 2021:1-9.
- 33. Magyari F, Pinczés LI, Páyer E, Farkas K, Ujfalusi S, Diószegi Á, et al. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies. *Annals of hematology*. 2022:1-9.
- 34. Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. *Cancer medicine*. 2020;9(22):8571-8.
- 35. Rodionov RN, Biener A, Spieth P, Achleitner M, Hölig K, Aringer M, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. *The Lancet Microbe*. 2021;2(4):e138.
- 36. Sait AS, Chiang TP, Marr KA, Massie AB, Cochran W, Shah P, et al. Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. *Transplantation direct*. 2022;8(1):e1268.
- 37. Weinbergerova B, Mayer J, Kabut T, Hrabovsky S, Prochazkova J, Kral Z, et al. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. *Hematological oncology*. 2021;39(5):715-20.
- 38. Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. *Blood.* 2020;136(20):2290-5.

- 39. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, et al. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. *Hematology/oncology and stem cell therapy*. 2021;14(1):65-70.
- 40. Adedoyin O, Brijmohan S, Lavine R, and Lisung FG. Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use. *BMJ case reports.* 2021;14(11).
- 41. Antony SJ, Singh J, de Jesus M, and Lance J. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation. *IDCases.* 2020;21:e00888.
- 42. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell.* 2020.
- 43. Bakhsh A, AlSaeed M, Ibrahim MA, AlHebaishi Y, AlBarrak M, AlAmro S, et al. Recovery From COVID-19 Pneumonia in a Heart Transplant Recipient: A Case Report. *Infectious diseases in clinical practice (Baltimore, Md).* 2021;29(6):e401-e3.
- 44. Balashov D, Trakhtman P, Livshits A, Kovalenko I, Tereshenko G, Solopova G, et al. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.* 2020:102983.
- 45. Basheer M, Saad E, Laskar O, Schuster O, Rechnitzer H, Zisman-Rozen S, et al. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery. *International journal of molecular sciences*. 2021;22(16).
- 46. Bayrak M, and Çadirci K. Successful pulsed methylprednisolone and convalescent plasma treatment in a case of a renal transplant recipient with COVID-19 positive pneumonia: a case report. *The Pan African medical journal.* 2021;38:273.
- 47. Bošnjak B, Odak I, Ritter C, Stahl K, Graalmann T, Steinbrück L, et al. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. *Frontiers in immunology*. 2021;12:721738.
- 48. Bronstein Y, Adler A, Katash H, Halutz O, Herishanu Y, and Levytskyi K. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. *Journal of medical virology*. 2022;94(3):1241-5.
- 49. Bruiners N, Guerrini V, Ukey R, Dikdan R, Yang J, Mishra PK, et al. Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms. *medRxiv.* 2022.
- 50. Casarola G, D'Abbondanza M, Curcio R, Alcidi R, Campanella T, Rossi R, et al. Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report. *Clinical infection in practice*. 2021;12:100096.
- 51. Chen L, Zody MC, Mediavilla JR, Cunningham MH, Composto K, Chow KF, et al. Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. *mSphere*. 2021;6(4):e0048021.
- 52. Choudhury A, Reddy GS, Venishetty S, Pamecha V, Shasthry SM, Tomar A, et al. COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery. *Journal of clinical and translational hepatology*. 2020;8(4):467-73.
- 53. Christensen J, Kumar D, Moinuddin I, Bryson A, Kashi Z, Kimball P, et al. Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients. *Transplantation proceedings*. 2020;52(9):2637-41.
- 54. Çınar OE, Sayınalp B, Aladağ Karakulak E, Avşar Karataş A, Velet M, İnkaya A, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2020;59(5):102821.

- 55. Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. *British journal of haematology*. 2020;190(3):e154-e6.
- 56. Colombo D, Gatti A, Alabardi P, Bompane D, Bonardi G, Mumoli N, et al. COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma. *Journal of hematology*. 2022;11(2):77-80.
- 57. Cusi MG, Conticini E, Gandolfo C, Anichini G, Savellini GG, Valente S, et al. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience. *BMC Infect Dis.* 2021;21(1):630.
- 58. D'Abramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E, et al. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. *Frontiers in immunology*. 2022;13:911339.
- 59. Dale M, Sogawa H, Seyedsaadat SM, Wolf DC, Bodin R, Partiula B, et al. Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients. *Transplantation proceedings*. 2021;53(4):1175-9.
- 60. Delgado-Fernández M, García-Gemar GM, Fuentes-López A, Muñoz-Pérez MI, Oyonarte-Gómez S, Ruíz-García I, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency Three consecutive cases and review of the literature. *Enfermedades infecciosas y microbiologia clinica (English ed)*. 2021.
- 61. Dell'Isola GB, Felicioni M, Ferraro L, Capolsini I, Cerri C, Gurdo G, et al. Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection. *Frontiers in pediatrics*. 2021;9:712603.
- 62. Deveci B, and Saba R. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports. *Medicine*. 2021;100(52):e28470.
- 63. Di Palma M, Gentilini E, Masucci C, Micozzi A, Turriziani O, Mulè A, et al. Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report. *Mediterranean journal of hematology and infectious diseases*. 2022;14(1):e2022043.
- 64. Erber J, Wiessner JR, Huberle C, Schneider J, Mijočević H, von Bomhard D, et al. Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 A case series. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2021;60(6):103278.
- 65. Ferrari S, Caprioli C, Weber A, Rambaldi A, and Lussana F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. *Leukemia & lymphoma*. 2021;62(6):1490-6.
- 66. Fung M, Nambiar A, Pandey S, Aldrich JM, Teraoka J, Freise C, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. *Transplant infectious disease : an official journal of the Transplantation Society*. 2021;23(2):e13477.
- 67. Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, et al. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy. *Clinical lymphoma, myeloma & leukemia.* 2021;21(9):e731-e5.
- 68. Gattuso G, Schiavello E, Oltolini C, Biassoni V, Terenziani M, Chiaravalli S, et al. Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management? *Tumori.* 2021:3008916211067825.
- 69. Gordon O, Brosnan MK, Yoon S, Jung D, Littlefield K, Ganesan A, et al. Pharmacokinetics of hightiter anti-SARS-CoV-2 human convalescent plasma in high-risk children. *JCl insight*. 2022;7(2).
- 70. Gupta A, Kute VB, Patel HV, Engineer DP, Banerjee S, Modi PR, et al. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study. *Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation*. 2021;19(4):304-9.

- 71. Halfmann PJ, Minor NR, Haddock LA, Maddox R, Moreno GK, Braun KM, et al. Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. 2022:2022.04.11.22272784.
- 72. Hanssen JLJ, Stienstra J, Boers SA, Pothast CR, Zaaijer HL, Tjon JM, et al. Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity? *Infectious disease reports*. 2021;13(4):855-64.
- 73. Hartman W, Hess A, and Connor J. Use of COVID-19 Convalescent Plasma as Prophylaxis in a Patient with New Onset All. *Clin Oncol Case Rep.* 2021;4.
- 74. Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, et al. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. *Cell reports Medicine*. 2021;2(1):100164.
- 75. Hovey JG, Tolbert D, and Howell D. Burton's Agammaglobulinemia and COVID-19. *Cureus.* 2020;12(11):e11701.
- 76. Hughes CM, Gregory GP, Pierce AB, Druce JD, Catton M, Chong B, et al. Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. *Infection control and hospital epidemiology*. 2022;43(6):820-2.
- 77. Iaboni A, Wong N, and Betschel SD. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma. *Journal of clinical immunology*. 2021;41(5):923-5.
- 78. Jamir I, Lohia P, Pande RK, Setia R, Singhal AK, and Chaudhary A. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. *Annals of hepato-biliary-pancreatic surgery*. 2020;24(4):526-32.
- 79. Jassem J, Marek-Trzonkowska NM, Smiatacz T, Arcimowicz Ł, Papak I, Jassem E, et al. Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report. *International journal of molecular sciences*. 2021;22(20).
- 80. Jiang J, Miao Y, Zhao Y, Lu X, Zhou P, Zhou X, et al. Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications. *Clinical transplantation*. 2020;34(9):e14025.
- 81. Jin H, Reed JC, Liu STH, Ho HE, Lopes JP, Ramsey NB, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. *The journal of allergy and clinical immunology In practice*. 2020;8(10):3594-6.e3.
- 82. Karaolidou F, Loutsidi NE, Mellios Z, Jahaj E, Eleftheriou K, Pagoni M, et al. Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report. *Respirol Case Rep.* 2021;9(12):e0858.
- 83. Karataş A, İnkaya A, Demiroğlu H, Aksu S, Haziyev T, Çınar OE, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2020;59(5):102871.
- 84. Katz-Greenberg G, Yadav A, Gupta M, Martinez-Cantarin MP, Gulati R, Ackerman L, et al. Outcomes of COVID-19-positive kidney transplant recipients: A single-center experience. *Clinical nephrology.* 2020;94(6):318-21.
- 85. Keitel V, Bode JG, Feldt T, Walker A, Müller L, Kunstein A, et al. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure. *Frontiers in immunology*. 2021;12:645989.
- 86. Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. *Nature.* 2021.
- 87. Kenig A, Ishay Y, Kharouf F, and Rubin L. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. *Clinical immunology (Orlando, Fla).* 2021:108723.

- 88. Ketels T, Gisolf J, Claassen M, Swanink C, van Lochem E, Moonen L, et al. Short Communication: Prolonged COVID-19 Infection in a Patient with Newly Diagnosed HIV/AIDS. *AIDS research and human retroviruses.* 2022;38(5):399-400.
- 89. Khan AM, Ajmal Z, Raval M, and Tobin E. Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge. *Cureus*. 2020;12(8):e9629.
- 90. Khatamzas E, Rehn A, Muenchhoff M, Hellmuth J, Gaitzsch E, Weiglein T, et al. Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. 2021:2021.01.10.20248871.
- 91. Khatri A, Chang KM, Berlinrut I, and Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient Case report and review of literature. *Journal de mycologie medicale*. 2021;31(2):101125.
- 92. Kluger MA, Czogalla J, Schmidt-Lauber C, Peine S, Schmiedel S, Bangert K, et al. Convalescent plasma treatment for early post-kidney transplant acquired COVID-19. *Transplant infectious disease* : an official journal of the Transplantation Society. 2021;23(4):e13685.
- 93. Kremer AE, Kremer AN, Willam C, Völkl S, Verhagen J, Achenbach S, et al. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. *European journal of immunology*. 2021;51(10):2478-84.
- 94. Lancman G, Mascarenhas J, and Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. *Journal of hematology & oncology.* 2020;13(1):131.
- 95. Lang-Meli J, Fuchs J, Mathé P, Ho HE, Kern L, Jaki L, et al. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. *Journal of clinical immunology*. 2022;42(2):253-65.
- 96. Lazzari L, Oltolini C, Ciceri F, and Giglio F. Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant. *BMJ case reports.* 2021;14(10).
- 97. Lemus HN, Alkayyali M, Kim E, Cunnigham-Rundles C, Pyburn D, and Abrams R. Acute Cerebellitis and Myeloradiculitis Associated With SARS-CoV-2 Infection in Common Variable Immunodeficiency-A Case Report. *The Neurohospitalist.* 2022;12(2):361-5.
- 98. Lima B, Gibson GT, Vullaganti S, Malhame K, Maybaum S, Hussain ST, et al. COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes. *Transplant infectious disease : an official journal of the Transplantation Society*. 2020;22(5):e13382.
- 99. Lindemann M, Krawczyk A, Dolff S, Konik M, Rohn H, Platte M, et al. SARS-CoV-2-specific humoral and cellular immunity in renal transplant and haemodialysis patients treated with convalescent plasma. 2020:2020.12.09.20239673.
- 100. London J, Boutboul D, Lacombe K, Pirenne F, Heym B, Zeller V, et al. Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy. *Journal of clinical immunology*. 2020:1-6.
- 101. Lubnow M, Schmidt B, Fleck M, Salzberger B, Müller T, Peschel G, et al. Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2021;103:624-7.
- 102. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, et al. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. *Blood advances*. 2020;4(19):4864-8.
- 103. Madariaga MLL, Guthmiller JJ, Schrantz S, Jansen MO, Christensen C, Kumar M, et al. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. <u>https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13185</u>. Accessed Feb 5, 2021, n/a.
- 104. Martens T, Hens L, De Pauw M, and Van Belleghem Y. Heart Transplantation Complicated by COVID-19 Infection. *The Annals of thoracic surgery*. 2022;113(4):e267-e9.
- 105. Martínez-Barranco P, García-Roa M, Trelles-Martínez R, Arribalzaga K, Velasco M, Guijarro C, et al. Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma. *Acta haematologica*. 2021.

- 106. Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, Fernández-Román IM, López-Barba J, de la Cruz-Merino L, et al. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. *Frontiers in immunology*. 2022;13:860891.
- 107. Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, et al. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2021;73(7):e1762-e5.
- 108. Mehta SA, Rana MM, Motter JD, Small CB, Pereira MR, Stosor V, et al. Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. *Transplantation*. 2021;105(1):216-24.
- 109. Mendes-Correa MC, Vilas-Boas LSS, Bierrenbach AL, Vincente de Paula A, Tozetto-Mendoza TR, Leal FE, et al. Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant. 2021:2021.05.11.21256908.
- 110. Milošević I, Jovanović J, and Stevanovic O. Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. *Journal of infection in developing countries*. 2020;14(11):1248-51.
- 111. Mira E, Yarce OA, Ortega C, Fernández S, Pascual NM, Gómez C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. *The journal of allergy and clinical immunology In practice.* 2020;8(8):2793-5.
- 112. Mohseni M, Albus M, Kaminski A, and Harrison MF. A Case of COVID-19 Re-Infection in a Liver Transplant Patient. *Cureus*. 2021;13(5):e14916.
- 113. Monrad I, Sahlertz SR, Nielsen SSF, Pedersen L, Petersen MS, Kobel CM, et al. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. *Open forum infectious diseases*. 2021;8(7):ofab295.
- 114. Moore JL, Ganapathiraju PV, Kurtz CP, and Wainscoat B. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. *The American journal of case reports.* 2020;21:e927812.
- 115. Moutinho-Pereira S, Calisto R, Sabio F, and Guerreiro L. High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection. *BMJ case reports*. 2021;14(8).
- 116. Naeem S, Gohh R, Bayliss G, Cosgrove C, Farmakiotis D, Merhi B, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. *Transplant infectious disease : an official journal of the Transplantation Society.* 2020:e13451.
- 117. Nguyen MC, Lee EJ, Avery RK, Dioverti-Prono MV, Shoham S, Tobian AAR, et al. Transplant of SARS-CoV-2-infected Living Donor Liver: Case Report. *Transplantation direct.* 2021;7(8):e721.
- 118. Niu A, McDougal A, Ning B, Safa F, Luk A, Mushatt DM, et al. COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. *Bone marrow transplantation*. 2020:1-3.
- 119. Nussenblatt V, Roder A, Das S, de Wit E, Youn J-H, Banakis S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. 2021:2021.10.02.21264267.
- 120. Nyström K, Hjorth M, Fust R, Nilsdotter-Augustinsson Å, Larsson M, Niward K, et al. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. *BMC Infect Dis.* 2022;22(1):362.
- 121. Oliva A, Cancelli F, Brogi A, Curtolo A, Savelloni G, Siccardi G, et al. Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature. *The new microbiologica*. 2022;45(1):62-72.
- 122. Ordaya EE, Abu Saleh OM, Stubbs JR, and Joyner MJ. Vax-Plasma in Patients With Refractory COVID-19. *Mayo Clin Proc.* 2022;97(1):186-9.
- 123. Ormazabal Vélez I, Induráin Bermejo J, Espinoza Pérez J, Imaz Aguayo L, Delgado Ruiz M, and García-Erce JA. Two patients with rituximab associated low gammaglobulin levels and relapsed

covid-19 infections treated with convalescent plasma. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2021;60(3):103104.

- 124. Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, et al. Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. *Annals of Oncology*. 2021.
- 125. Prasad RM, Srivastava S, Wang E, Liu JZ, Gami R, Abdelgadir A, et al. Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse. *The Permanente journal*. 2021;26(1):123-31.
- 126. Rüfenacht S, Gantenbein P, Boggian K, Flury D, Kern L, Dollenmaier G, et al. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series. *Infection*. 2022;50(3):783-90.
- 127. Ribeiro LC, Benites BD, Ulaf RG, Nunes TA, Costa-Lima C, Addas-Carvalho M, et al. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma. *Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.* 2021;17(1):14.
- 128. Rnjak D, Ravlić S, Šola AM, Halassy B, Šemnički J, Šuperba M, et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? *Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine*. 2021;28(3):264-70.
- 129. Rodriguez JA, Bonnano C, Khatiwada P, Roa AA, Mayer D, and Eckardt PA. COVID-19 Coinfection with Mycobacterium abscessus in a Patient with Multiple Myeloma. *Case reports in infectious diseases.* 2021;2021:8840536.
- 130. Rodriguez-Pla A, Vikram HR, Khalid V, and Wesselius LJ. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. *Rheumatology international*. 2021;41(8):1509-14.
- 131. Schenker C, Hirzel C, Walti LN, Zeerleder SS, Andres M, Ramette A, et al. Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response. *British journal of haematology*. 2022;196(3):e27-e9.
- 132. Schreiber A, Elango K, Hong K, and Ahsan C. Cardiac transplant recipient with COVID-19 induced acute hypoxic respiratory failure: a case report. *European heart journal Case reports.* 2021;5(6):ytab217.
- 133. Sepulcri C, Dentone C, Mikulska M, Bruzzone B, Lai A, Fenoglio D, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient a case study. *Open forum infectious diseases.* 2021;ofab217:2021.01.23.21249554.
- 134. Shankar R, Radhakrishnan N, Dua S, Arora S, Rana M, Sahu DK, et al. Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2021;60(1):102956.
- 135. Spinicci M, Mazzoni A, Borchi B, Graziani L, Mazzetti M, Bartalesi F, et al. AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection.n/a(n/a).
- 136. Steiner S, Schwarz T, Corman VM, Gebert L, Kleinschmidt MC, Wald A, et al. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. *Frontiers in immunology*. 2022;13:840126.
- 137. Szwebel TA, Veyer D, Robillard N, Eshagh D, Canoui E, Bruneau T, et al. Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. *Stem Cell Rev Rep.* 2021;17(1):296-9.
- 138. Taha Y, Wardle H, Evans AB, Hunter ER, Marr H, Osborne W, et al. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. *Annals of clinical microbiology and antimicrobials.* 2021;20(1):85.

- 139. Trimarchi H, Gianserra R, Lampo M, Monkowski M, and Lodolo J. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. *Clinical kidney journal*. 2020;13(5):739-41.
- 140. Van Damme KFA, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels C, et al. Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. *Frontiers in immunology*. 2020;11:596761.
- 141. van Oers NSC, Hanners NW, Sue PK, Aquino V, Li QZ, Schoggins JW, et al. SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. *Clinical immunology (Orlando, Fla).* 2021;224:108662.
- 142. Wright Z, Bersabe A, Eden R, and Cap A. Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma. *Clinical lymphoma, myeloma & leukemia.* 2020.
- 143. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *Journal of medical virology*. 2020.
- 144. Zhang LB, Pang RR, Qiao QH, Wang ZH, Xia XY, Wang CJ, et al. Successful recovery of COVID-19associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma. *Military Medical Research*. 2020;7(1):45.
- 145. Zhang LL, Liu Y, Guo YG, Chang J, Gao B, Li ZZ, et al. Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis. *Turkish journal of haematology : official journal of Turkish Society of Haematology*. 2020.
- 146. Zimmerli A, Monti M, Fenwick C, Eckerle I, Beigelman-Aubry C, Pellaton C, et al. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. *Frontiers in immunology*. 2021;12:613502.
- 147. Zimmermann J, Glueck OM, Fertmann JM, Sienel WG, Yavuz G, Damirov F, et al. COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies. *Transplantation* proceedings. 2022.
- 148. Franchini M, Focosi D, Percivalle E, Beccaria M, Garuti M, Arar O, et al. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. *Viruses*. 2022;14(7).
- 149. Belcari G, Conti A, Mazzoni A, Lanza M, Mazzetti P, and Focosi D. Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia. *Life* (*Basel, Switzerland*). 2022;12(7).
- 150. Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman M, et al. Prolonged SARS-CoV-2 replication in an immunocompromised patient. *J Infect Dis.* 2020.
- 151. McKemey E, Shields AM, Faustini SE, Hill HJ, Barnskaya A, Stamataki Z, et al. Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia. *Journal of clinical immunology*. 2021;41(5):926-9.
- 152. Pal P, Ibrahim M, Niu A, Zwezdaryk KJ, Tatje E, Robinson WRt, et al. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. *Transfusion medicine* (*Oxford, England*). 2021;31(3):217-20.
- 153. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *The Journal of allergy and clinical immunology*. 2021;147(2):520-31.
- 154. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. *Nat Commun.* 2020;11(1):6385.
- 155. Hatzl S, Eisner F, Schilcher G, Kreuzer P, Gornicec M, Eller P, et al. Response to "COVID-19 in persons with haematological cancers". *Leukemia*. 2020;34(8):2265-70.
- 156. Reuken PA, Stallmach A, Pletz MW, Brandt C, Andreas N, Hahnfeld S, et al. Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection. *Leukemia*. 2021;35(3):920-3.
- 157. Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. *EBioMedicine*. 2021;67:103355.

- 158. Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. *Journal of hematology & oncology*. 2020;13(1):94.
- 159. Rahman F, Liu STH, Taimur S, Jacobs S, Sullivan T, Dunn D, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City. *Clinical transplantation*. 2020:e14089.
- 160. Kutzler HL, Poulos CM, Cheema F, O'Sullivan DM, Ali A, Ebcioglu Z, et al. COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut. *Transplantation*. 2021;105(1):e6-e8.
- 161. Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
- 162. Ho HE, Mathew S, Peluso MJ, and Cunningham-Rundles C. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. *The journal of allergy and clinical immunology In practice*. 2021;9(1):490-3.e2.
- 163. Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia*. 2022.
- 164. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Accessed online at <u>https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</u> on February 9, 2022.
- 165. Clinical Practice Guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Accessed online at https://www.aabb.org/docs/default-source/default-document-library/regulatory/clinical-practice-guidelines-from-aabb-ccp.pdf?sfvrsn=e24ea825 0 on August 2, 2022.
- 166. Casadevall A, Pirofski LA, and Joyner MJ. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. *mBio.* 2021;12(2).
- 167. Mukhina OA, Fomina DS, Parshin VV, Gushchin VA, Dolzhikova IV, Shchetinin AM, et al. SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case. *Human vaccines & immunotherapeutics.* 2022:2101334.
- 168. Focosi D, Tuccori M, Antonelli G, and Maggi F. What is the optimal usage of Covid-19 convalescent plasma donations? *Clin Microb Infect.* 2020;S1198-743X(20):30589-9.
- 169. Sample, I. Doctors treat first UK patient in Covid 'super donor 'blood trial. The Guardian. Accessed online at <u>https://www.theguardian.com/world/2022/jun/30/doctors-treat-first-uk-patient-covid-super-donor-blood-trial-antibodies</u> on August 3, 2022.
- 170. Focosi D, Franchini M, Joyner MJ, Casadevall A, and Sullivan DJ. Analysis of anti-Omicron neutralizing antibody titers in plasma from pre-Omicron convalescents and vaccinees. 2021:2021.12.24.21268317.